Business Of Biotech Podcast Por Ben Comer arte de portada

Business Of Biotech

Business Of Biotech

De: Ben Comer
Escúchala gratis

The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.

© 2026 Business Of Biotech Ciencia Ciencias Biológicas Economía Gestión Gestión y Liderazgo
Episodios
  • Investing In Early-Stage Oncology With Yosemite's Dan McHugh

    Investing In Early-Stage Oncology With Yosemite's Dan McHugh
    Mar 30 2026

    We love to hear from our listeners. Send us a message.

    On this week's episode of the Business of Biotech, Dan McHugh, head of the investment team at Yosemite, explains the San Francisco VC group's approach to investing in early-stage cancer therapeutics and funding academic research through unrestricted grants. Founded by Reed Jobs, son of Steve Jobs and Laurene Powell Jobs, Yosemite invests across drug modalities and supporting technologies in the oncology space. Dan talks about his path from bioengineering to biotech venture capital, meeting Reed Jobs on Stanford's fencing team, his CEO turn at Tune Therapeutics, and the current fundraising environment for innovative science.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
    Más Menos
    56 m
  • Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash

    Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash
    Mar 23 2026

    We love to hear from our listeners. Send us a message.

    On this week's episode of the Business of Biotech we're speaking with Alan Bash, President, Carvykti, at Legend Biotech, about how Carvykti became a blockbuster, category-leading CAR T therapy for multiple myeloma. Alan talks about manufacturing and delivering an autologous cell therapy at commercial scale, Legend Biotech's partnership with Johnson & Johnson, lessons he learned at Bristol Myers Squibb, Checkmate Pharmaceuticals, and ZielBio, and his strategy for growing Carvykti's patient footprint and facing new competitors in the market.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
    Más Menos
    51 m
  • Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.

    Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.
    Mar 16 2026

    We love to hear from our listeners. Send us a message.

    On this week's episode of the Business of Biotech we speak with Dr. Marc Hedrick, M.D., President and CEO at Plus Therapeutics, about the company's pivot from cell therapy to radiotherapeutics for brain cancers, and what's behind the choice of Rhenium-186 as the radioisotope for its lead development candidate, Reyobiq. We'll talk about Plus Therapeutics' diagnostic subsidiary, CNSide, and hear from Marc about recent FDA meetings and the agency's attitude toward novel radiotherapeutics.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
    Más Menos
    54 m
Todavía no hay opiniones